Related posts
Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 1 opinions in the last 12 months.
Despite the setback from the Roundup litigation, Bayer AG seems to be on the right track with new drugs on the pharma side and plans to spin out the herbicide business. Experts believe that the stock is currently priced at an attractive level and may present a good opportunity for investors. The company's acquisition of Monsanto in 2018 has been a major factor impacting its performance, but the situation is being addressed.
On these big Chemicals you are always best to wait for an opportunity to get in. There isn't an urgent rush. This company is a monstrously big company.
Bayer AG is a American stock, trading under the symbol BAYRY-OTC on the US OTC (BAYRY). It is usually referred to as OTC:BAYRY or BAYRY-OTC
In the last year, there was no coverage of Bayer AG published on Stockchase.
Bayer AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Bayer AG.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Bayer AG In the last year. It is a trending stock that is worth watching.
On 2024-03-27, Bayer AG (BAYRY-OTC) stock closed at a price of $7.67.
It is priced at 50 cents on the dollar compared to its peers. In 2018 it bought Monsanto and the Roundup litigation halved the company. However it is being dealt with. It has three new drugs on the pharma side, one with no near term competitors when it comes off patent. It will probably spin out the herbicide business and sits at a very attractive price. Buy 18 Hold 8 Sell 1